lestaurtinib has been researched along with midostaurin in 28 studies
| Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) | Studies (midostaurin) | Trials (midostaurin) | Recent Studies (post-2010) (midostaurin) |
|---|---|---|---|---|---|
| 124 | 12 | 63 | 491 | 36 | 286 |
| Protein | Taxonomy | lestaurtinib (IC50) | midostaurin (IC50) |
|---|---|---|---|
| Aurora kinase A | Homo sapiens (human) | 0.08 | |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | 0.142 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.109 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.25 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.1663 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 7.5767 | |
| AP2-associated protein kinase 1 | Homo sapiens (human) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (42.86) | 29.6817 |
| 2010's | 12 (42.86) | 24.3611 |
| 2020's | 4 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
| Ashman, LK; Griffith, R; Mashkani, B | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Dewhurst, S; Gelbard, HA; Goodfellow, VS; Loweth, CJ; Marker, DF; Nguyen, T; Polesskaya, O; Pollack, S; Ravula, SB; Sheppard, D; Todd, DE; Wiemann, T; Xu, Y | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S | 1 |
| Zhang, GS | 1 |
| Kiyoi, H | 2 |
| Berdel, WE; Müller-Tidow, C; Serve, H; Tickenbrock, L | 1 |
| Brown, P; Cohen, P; Deangelo, D; Estey, E; Galinsky, I; Giles, F; Kantarjian, H; Karp, JE; Levis, M; Pham, R; Roesel, J; Small, D; Smith, BD; Stine, A; Stone, R; Wang, Y | 1 |
| Austin, SJ; Burnett, AK; Gilkes, AF; Knapper, S; Mills, KI; Walsh, V | 1 |
| Ehninger, G; Illmer, T | 1 |
| Tallman, M | 1 |
| Gore, SD | 1 |
| Karp, J | 1 |
| Burnett, A; Lo-Coco, F; Löwenberg, B; Sanz, M | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X | 1 |
| Chabner, BA; Fathi, AT | 1 |
| Freeman, C; Giles, F; Swords, R | 1 |
| Bharate, SB; Sawant, SD; Singh, PP; Vishwakarma, RA | 1 |
| Bai, Y; Bennett, K; Colinge, J; Eschrich, S; Fang, B; Grebien, F; Haura, EB; Kim, JY; Koomen, J; Li, J; Okamoto, I; Qian, X; Rawal, B; Rix, U; Schell, M; Song, L; Stukalov, A; Superti-Furga, G; Winter, G; Yoshida, T; Zhang, G | 1 |
| Courts, C; Gallala, H; Janzen, V; Kraus, D; Nowak, M; Perner, S; Probstmeier, R; Veit, N; Winter, J | 1 |
| Asami, Y; Crump, A; Ōmura, S | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
10 review(s) available for lestaurtinib and midostaurin
| Article | Year |
|---|---|
[Possibility of targeting FLT3 kinase for the treatment of leukemia].
Topics: Animals; Antibodies, Monoclonal; Benzoquinones; Carbazoles; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Lactams, Macrocyclic; Leukemia; Mutation; Piperazines; Pyrroles; Quinazolines; Quinones; Rifabutin; Staurosporine; Sunitinib | 2005 |
Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Topics: Animals; Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Staurosporine | 2006 |
[Novel molecularly target therapies for leukemia].
Topics: Antineoplastic Agents; Carbazoles; Farnesyltranstransferase; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia; Piperazines; Quinazolines; Staurosporine | 2007 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
FLT3 inhibition as a targeted therapy for acute myeloid leukemia.
Topics: Acute Disease; Animals; Carbazoles; Drug Evaluation, Preclinical; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid; Molecular Structure; Mutation; Staurosporine | 2009 |
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine | 2012 |
Kinase inhibitors of marine origin.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Aquatic Organisms; Aza Compounds; Carbazoles; Chemistry, Pharmaceutical; Depsipeptides; Furans; Humans; Indoles; Naphthyridines; Peptides, Cyclic; Phosphoinositide-3 Kinase Inhibitors; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Pyrimidines; Staurosporine; Terpenes | 2013 |
Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Carbazoles; Drug Discovery; Furans; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Staurosporine | 2018 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
18 other study(ies) available for lestaurtinib and midostaurin
| Article | Year |
|---|---|
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
Topics: Benzamides; Binding Sites; Carbazoles; Computer Simulation; Dasatinib; Drug Design; Furans; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Staurosporine; Sunitinib; Thiazoles | 2010 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Blood-Brain Barrier; Brain; Carbazoles; Cells, Cultured; Cognition Disorders; Drug Discovery; HIV Infections; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase Kinase Kinase 11; Models, Chemical; Molecular Structure; Monocytes; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Pyrroles; tat Gene Products, Human Immunodeficiency Virus; Tumor Necrosis Factor-alpha | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship | 2022 |
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine | 2005 |
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Topics: Antineoplastic Agents; Carbazoles; Case-Control Studies; Cell Line; Cell Survival; Cells, Cultured; Drug Screening Assays, Antitumor; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Inhibitory Concentration 50; Leukemia; Pharmacokinetics; Plasma; Staurosporine | 2006 |
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.
Topics: Acute Disease; Adolescent; Adult; Aged; Apoptosis; Blast Crisis; Carbazoles; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid; Male; Middle Aged; Mutation; Protein Kinase C; Protein-Tyrosine Kinases; Signal Transduction; Staurosporine; Tumor Cells, Cultured | 2006 |
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin | 2008 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2011 |
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Topics: Antineoplastic Agents; Benzothiazoles; Carbazoles; Clinical Trials as Topic; Cytokines; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib; Tandem Repeat Sequences | 2011 |
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
Topics: Antineoplastic Agents; Carbazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Furans; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasm Proteins; Phosphorylation; Protein Interaction Maps; Protein Kinase Inhibitors; Quinazolines; Staurosporine | 2013 |
Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells.
Topics: Carbazoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Furans; Humans; Indole Alkaloids; Polyploidy; Signal Transduction; Small Cell Lung Carcinoma; Staurosporine | 2015 |